Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

Ephenidine

Ephenidine molecule structureEphenidine molecule structure
N-Ethyl-1,2-diphenylethanamine
NEDPA, EPE
Psychoactive Class
Chemical Class

Ephenidine is a dissociative anesthetic of the diarylethylamine class that acts as an NMDA receptor antagonist.citation needed It emerged on research chemical markets in early 2015 and has been sold online as a designer drug. Structurally related to diphenidine and MXP, ephenidine is widely reported to produce a smoother dissociative experience compared to those compounds. Very little is known about this substance, and considerable caution is warranted given the limited safety data available.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~50 mg
Light50-110 mg
Moderate110-150 mg
Strong150-200 mg
Heavy200+ mg

Strong tolerance develops rapidly, requiring progressively larger doses to achieve the same effects; tolerance is reported to return to baseline after 1 to 2 weeks of abstinence.

Duration

Onset10-30 minutes
Peak2-4 hours
After Effects1-6 hours
Total5-7 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

The subjective physical effects of ephenidine can be broken down into several components which progressively intensify proportional to dosage.

Tactile disconnectionPhysical autonomyIncreased heart rate

Cognitive

The general head space of ephenidine is often described as particularly euphoric and clear-headed in comparison to that of DXM and ketamine.

Visual

Distortions

Ephenidine exhibits a full array of dissociative distortions and alterations in visual perception.

Geometry

The visual geometry found within ephenidine can be described as very distinct and psychedelic when compared to that of ketamine, MXE, methoxphenidine and diphenidine. It is considerably less detailed than that of DXM. It does not extend beyond level 5 and can be comprehensively described as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.

Hallucinatory States

At high doses, ephenidine can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics.

Suppressions

Visual acuity suppression

Auditory

The auditory effects are common in their occurrence and exhibit a range of effects.

Forked from Subjective Effect Documentation byJosie Kins July 2015.

See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → orange2 → brown1
Mandelin(MD)
yellow2 → green3
Liebermann(LB)
white → orange2 → red2
Froe(FR)
white → yellow1
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

Ephenidine acts primarily as an NMDA receptor antagonist with a binding affinity (Ki) of 66.4 nM. It also displays weaker affinity for the dopamine transporter (Ki = 379 nM) and norepinephrine transporter (Ki = 841 nM), as well as sigma-1 (Ki = 629 nM) and sigma-2 (Ki = 722 nM) receptor binding sites.1

Pharmacokinetics

Ephenidine's metabolic pathway involves N-oxidation, N-dealkylation, and hydroxylation of both the benzyl and phenyl rings, with phenyl ring hydroxylation occurring only after N-dealkylation. Dihydroxy metabolites are conjugated by methylation of one hydroxy group, while monohydroxy metabolites undergo glucuronidation or sulfation.

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
A very strong tolerance buildup occurs with repeated ephenidine use, resulting in the need to consume increasingly large doses to achieve the same level of effects.
Cross Tolerance

Dissociatives, NMDA receptor antagonists

Baseline Reset
Tolerance is reported to reset to baseline after 1-2 weeks of abstinence.

Harm Potential

Addiction & Dependence

Psychological

Classified as habit-forming with compulsive redosing commonly reported as an effect. The overall addictive potential has not been formally studied and remains unknown.citation needed

Psychosis Risk

At high doses, ephenidine is capable of producing internal hallucinations, warranting due care and attention.

History & Culture

Ephenidine emerged on the research chemical market in early 2015 as a dissociative anesthetic sold through online vendors as a designer drug.citation needed It was marketed as a potentially smoother alternative to other diarylethylamine dissociatives that were legally available

Trip Reports

Loading related reports

Preparing section content

Still loading. Refresh if this section does not appear.

Legality

By Country

Illegal3
Canada flagCanadaIllegal
Denmark flagDenmarkIllegal
United Kingdom flagUnited KingdomIllegal

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Ephenidine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.